Celyad SA Cultura de la Empresa

Dr. Christian Homsy, MD, MBA, has been the Chief Executive Officer and Executive Director of Celyad SA since July 2007. Dr. Homsy gained his business experience in senior research and development, marketing, business development and sales positions at Guidant Corporation, a leading medical device company active in the treatment of cardiovascular disease. He founded Guidant Institute for Therapy Development, a landmark facility for physician and health care professionals' education that gained international recognition and praise. Before joining Cardio3 BioSciences, he served as General Manager of Medpole, a European incubator dedicated to initiating the European operations for start-up companies in the medical device or biotechnology fields. He also holds a director mandate in Medpole SA. He obtained his Medical Doctorate at the University of Louvain and holds an MBA from the IMD in Lausanne (Switzerland).

Mr. Philippe Dechamps has been General Counsel and Company Secretary of Celyad SA since September 1, 2016 and serves as its Chief Legal Officer. Mr. Dechamps served as General Counsel and Corporate Secretary of Etablissements Delhaize Fr???res et Cie Le Lion (Groupe Delhaize) SA from March 5, 2015 to July 2016. He joined Delhaize Group in 1998, where he became General Counsel and Company Secretary in March 2015. Mr. Dechamps was part of the senior leadership team that successfully negotiated and finalized the merger of Delhaize Group and Royal Ahold in July 2016. Mr. Dechamps joined Delhaize Group in 2008 and served as its Senior Vice President and General Counsel of Europe & Asia. Prior to Delhaize Group, he started his legal career at the Brussels Bar with Linklaters (formerly, De Bandt) in 1994. He joined the legal team of Solvay in 1998 where he was mostly active in mergers and acquisitions. He then developed and managed the distribution contracts of the cardiovascular businesses of Guidant Corporation and Abbott Laboratories in Europe, Middle East and Africa for more than 5 years, before leaving the pharma and medical device industry. Mr. Dechamps holds a Master of Laws degree from Harvard Law School. He has also earned a Masters degree in European and International Laws from Vrije Universiteit Brussel Law School and a Master of Laws from University Catholique de Louvain.

Mr. Patrick Jeanmart has been the Chief Financial Officer at Celyad SA since September 2007 and serves as its Principal Accounting Officer. Mr. Jeanmart has spent the last 6 years working for IBA (Ion Beam Applications) where he held a number of senior financial management positions within several companies located in Belgium, Italy, UK and in the US. He served as Vice President of Finance of IBA Molecular from January 2004 to August 2007. Mr. Jeanmart has Master degree in Economics.

Dr. Jean-Pierre Latere has been the Chief Operating Officer of Celyad SA since January 11, 2017. Dr. Latere served as Vice President of Business Operations and Commercialization at Celyad SA until January 11, 2017. Dr. Latere served as Head of the Regenerative Medicine and Medical Device Franchise at Celyad SA since January 4, 2016 and also served as its Head of Cardiovascular Franchise. He joined Celyad in January 2016 and is responsible for building and leading the Company's Regenerative Medicine and Medical Device Franchise. He started his career as a Research Associate at the Michigan State University in the US. Following that assignment, he moved to the Johnson & Johnson group where he held various positions, from Scientist to Senior Scientist. He then joined Cardio3 BioSciences in 2008 as Project Manager Delivery System and left it in 2012 in the position of Senior Director Business Development. Dr. Latere served as Beauty Care and Healthcare Market Global Leader at Dow Corning. He holds a PhD in Chemistry from the University of Li???ge, Belgium.

Mr. Michel E. J. Lussier, MS, BME, MBA, serves as a Managing Director of Fjord Ventures. Mr. Lussier serves as the Chief Executive Officer of Metronom Health, Inc. He is a Co-Founder of Celyad SA (formerly Cardio3 BioSciences SA) and has been its Chairman of the Board since 2007. He served as the President of Clinical and Scientific Affairs Volcano Corporation since October 2012. He served as Group President of Clinical Affairs and EMEAI at Volcano Corporation since January 2012. He served as Group President of Advanced Imaging Systems Clinical & Scientific Affairs and Europe Africa and Middle East Operations at Volcano Corporation since January 2011. He served as the President of Volcano Europe & Clinical and Scientific Affairs at Volcano Corporation from July 2007 tp January 2011 and served as its Executive Vice President of Clinical & Scientific Affairs. He served as Managing Director of Volcano Europe at Volcano Corporation, since March 2006. He served as General Manager of European Operations and Vice President of InControl, Inc. From July 2002 to March 2006, he served as Vice President and General Manager for Africa, Middle East, European Operation, Global Clinical and Scientific Affairs at Volcano Corporation. Since July 2002, he served as Volcano's President. He joined Volcano Corp. in July, 2002. Prior to working with Volcano Therapeutics Inc., he was with Medtronic Corp. from 1980 to 1984, where he held number of positions varying from Clinical Engineering, Business Development, Sales and General Management at both the French and European levels. From 1990 to 1994, he served as Medtronic's European Business Director, Cardiac Pacing. From 1994 to 1998, he founded and led the European Subsidiary of InControl Corp., until its acquisition by Guidant in 1998. He joined InControl, Inc. in 1994 and served as its General Manager for European Operations and Vice President. He set up the European Operations in 6 countries and established a distributor network in 15 other countries. He joined Novoste Corp. in 1998. He served as Vice President for European Operations and General Manager for Europe of NOVT Corporation (formerly Novoste Corporation) from October 1998 to January 2002. He served as Vice President of the International Association of Prosthesis Manufacturers (IAPM). In February 2002, he founded MedPole S.A./N.V. a European distribution Incubator for medical device start up companies, located in Brussels. He has been the Chairman and Director at iSTAR Medical SA since April 27, 2015. Mr. Lussier holds a BS Degree in Electrical Engineering and a Master of Science's degree in Biomedical Engineering from the University of Montreal. He holds an M.B.A. from the European Institute of Business Administration-INSEAD in 1985.

Dr. Warren Sherman, M.D., F.A.C.C, F.S.C.A.I has been the Chief Medical Officer of Celyad SA (also known as Cardio3) since November 1, 2014. Dr. Sherman is a renowned American interventional cardiologist with more than 30 years' experience in the field of cardiology, with a focus in cell-based therapies for treating patients post myocardial infarction and with heart failure. Before joining Cardio3 BioSciences, Dr. Sherman was at the Columbia University Medical Center in New York, where he served in a number of capacities, including: Interventional Cardiologist at Columbia University Medical Center/NewYork-Presbyterian Hospital; Director of Stem Cell Research and Regenerative Medicine at the Center for Interventional Vascular Therapy; and Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Sherman is also the founder of the Cardiovascular Research Foundation's International Conference on Cell Therapy for Cardiovascular Disease (IC3D). He served as Director of Medical Education and Associate Director, Cardiac Catheterization Laboratories of The Zena and Michael A. Wiener Cardiovascular Institute of Mount Sinai Hospital New York, New York. In 1983, Dr. Sherman moved to Mount Sinai Hospital in New York to investigate new techniques for treating patients with acute myocardial infarction. In 1989, he shifted to a fully clinical role and created the Interventional Cardiology Program at Beth Israel Medical Center in New York City. With a deepening interest in myocardial regenerative techniques, Dr. Sherman pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of adult stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. This technique was then brought to the U.S., where he performed a similar procedure at Mount Sinai Hospital in April 2003. As Director of Cell Therapy at Mount Sinai Hospital, Dr. Sherman was the principal investigator of a multicenter clinical study of autologous skeletal myoblast injections for patients with congestive heart failure and the lead investigator on numerous translational studies. Mr. Sherman serves as Scientific and Clinical Advisor of Nexeon MedSystems Inc., Athersys, Inc. and BTHC VI, Inc. He serves as a Member of Scientific Advisory Board of Creative Medical Health, Inc. Mr. Sherman serves as Member of Scientific Advisory Board at U.S. Stem Cell, Inc. and Juventas Therapeutics, Inc. He served as a Director of Cardiac CellBased Endovascular Therapies, Columbia University Medical Center and New York Presbyterian Hospital. Dr. Sherman has authored or co-authored numerous publications in the emerging field of myocardial regeneration. He is certified by the American Board of Internal Medicine in Cardiology and Interventional Cardiology and serves as an advisor to a multitude of government organizations, societies and industries. Dr. Sherman received his BS degree from the Massachusetts Institute of Technology, medical degree from the State University of New York Upstate Medical School in Syracuse and his fellowship training at Oregon Health Sciences University, in Portland, Oregon.